Your Article Summary
See Latest ArticlesEffect of rifampin on the pharmacokinetics and pharmacodynamics of prasugrel in healthy male subjects
Current Medical Research and Opinion, 06/22/09
Farid NA et al. - Dose adjustment should not be necessary when prasugrel is administered with CYP inducers since formation of prasugrel's active metabolite is not affected by potent enzyme induction with rifampin.
Related Articles
Evaluation of Cynomolgus Monkey PXR, Primary Hepatocyte and In Vivo Pharmacokinetic Changes in Predicting Human CYP3A4 Induction
Drug Metabolism and Disposition, 10/21/09
Relevance Score: 89%
Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein inhibitor, in healthy subjects
British Journal of Clinical Pharmacology, 10/20/09
Relevance Score: 89%
Antiretroviral Adherence and Pharmacokinetics: Review of their Roles in Sustained Virologic Suppression
AIDS Patient Care and STDs, 10/05/09
Relevance Score: 89%
Pharmacokinetics after an intravenous single dose of the opioid ketobemidone in children
Acta Anaesthesiologica Scandinavica, 10/16/09
Relevance Score: 88%
Pharmacokinetic Outcomes of a Simplified, Weight-Based, Extended-Interval Gentamicin Dosing Protocol in Critically Ill Neonates
Pharmacotherapy, 10/27/09
Relevance Score: 87%
Today in Pharmacokinetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Safety of Oseltamivir Compared With the Adamantanes in Children Less Than 12 Months of Age
The Pediatric Infectious Disease Journal, 12/15/09
Evaluating pharmacokinetics and pharmacodynamics of intravenous busulfan in pediatric patients receiving bone marrow transplantation
Pediatric Transplantation, 12/15/09
'Party pill' drugs - BZP and TFMPP
New Zealand Medical Journal, 12/14/09